Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCMNYSE:HIMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$79.84-0.2%$80.33$57.52▼$117.19$31.37B1.464.36 million shs5.67 million shsHIMSHims & Hers Health$42.09-34.5%$48.71$13.47▼$72.98$14.37B2.0922.21 million shs173.04 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom0.00%-2.43%-5.34%+6.21%-31.41%HIMSHims & Hers Health0.00%+16.52%+17.46%+72.54%+191.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXCMDexCom4.8375 of 5 stars3.55.00.04.72.72.51.9HIMSHims & Hers Health2.4429 of 5 stars2.03.00.00.01.93.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.95Moderate Buy$98.5023.37% UpsideHIMSHims & Hers Health 2.00Hold$38.00-9.72% DownsideCurrent Analyst Ratings BreakdownLatest DXCM and HIMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold6/16/2025DXCMDexComTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$102.006/11/2025HIMSHims & Hers HealthMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$40.006/4/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$61.00 ➝ $65.005/30/2025DXCMDexComThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$104.005/22/2025DXCMDexComCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.00 ➝ $102.005/7/2025HIMSHims & Hers HealthDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/6/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMixed ➝ Mixed5/6/2025HIMSHims & Hers HealthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$35.00 ➝ $39.005/6/2025HIMSHims & Hers HealthCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell$25.00 ➝ $30.005/6/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$61.00 ➝ $61.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.03B7.76$2.24 per share35.59$5.38 per share14.84HIMSHims & Hers Health$1.48B6.38$0.23 per share182.36$2.16 per share19.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$576.20M$1.3459.5832.461.7112.90%30.05%10.00%7/24/2025 (Estimated)HIMSHims & Hers Health$126.04M$0.6961.0080.942.429.24%22.75%15.51%8/4/2025 (Estimated)Latest DXCM and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025HIMSHims & Hers Health$0.12$0.20+$0.08$0.20$535.21 million$586.01 million5/1/2025Q1 2025DXCMDexCom$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.551.501.32HIMSHims & Hers HealthN/A1.591.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%HIMSHims & Hers Health63.52%Insider OwnershipCompanyInsider OwnershipDXCMDexCom0.32%HIMSHims & Hers Health17.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom10,300392.11 million390.85 millionOptionableHIMSHims & Hers Health1,637223.83 million184.19 millionOptionableDXCM and HIMS HeadlinesRecent News About These CompaniesHIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation With the Schall Law FirmJune 23 at 7:41 PM | businesswire.comHIMS INVESTIGATION ALERT: Investigation Launched into Hims & Hers Health, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law FirmJune 23 at 7:10 PM | prnewswire.comHims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for InvestorsJune 23 at 6:46 PM | zacks.comHims & Hers Health, Inc. (HIMS) Shares Crash After Novo Nordisk Cancels Partnership Over “Deceptive†Marketing of Wegovy, Faces Investor Scrutiny – Hagens BermanJune 23 at 6:00 PM | globenewswire.comHIMS BREAKING NEWS: Hims & Hers Health, Inc. is being Investigated for Securities Fraud; Investors with Losses are Notified to Contact BFA LawJune 23 at 5:57 PM | businesswire.comNovo sends Hims packingJune 23 at 5:51 PM | ft.comWhy Hims & Hers Health Stock Is Crashing TodayJune 23 at 4:24 PM | fool.comHims & Hers Health, Inc. (HIMS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationJune 23 at 4:24 PM | businesswire.comMid Cap Stocks To Research - June 23rdJune 23 at 4:04 PM | marketbeat.comHIMS Stock Crashes 30% in a Day: Time to Buy the Dip?June 23 at 3:51 PM | zacks.comHims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – HIMSJune 23 at 3:36 PM | businesswire.comWeight Loss Woes: Hims & Hers (HIMS) Shares Under PressureJune 23 at 3:05 PM | youtube.comHims & Hers Health (NYSE:HIMS) Stock Price Down 28.5% - Here's What HappenedJune 23 at 2:55 PM | marketbeat.comTop Medical Stocks To Follow Today - June 23rdJune 23 at 2:10 PM | marketbeat.comTop Healthcare Stocks Worth Watching - June 23rdJune 23 at 2:10 PM | marketbeat.comSecurities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. CruzJune 23 at 2:06 PM | businesswire.comNYSE: HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Significant Losses to Contact the FirmJune 23 at 2:01 PM | businesswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & HersJune 23 at 1:35 PM | businesswire.comNovo Nordisk Ends Partnership with Hims & HersJune 23 at 12:58 PM | wsj.comHims & Hers Health (NYSE:HIMS) Shares Gap Down - Time to Sell?June 23 at 12:46 PM | marketbeat.comNeedham & Company LLC Downgrades Hims & Hers Health (NYSE:HIMS) to HoldJune 23 at 12:25 PM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingHims & Hers Stock: Buy the Dip or Wait It Out?By Gabriel Osorio-Mazilli | June 5, 2025View Hims & Hers Stock: Buy the Dip or Wait It Out?DXCM and HIMS Company DescriptionsDexCom NASDAQ:DXCM$79.84 -0.16 (-0.20%) Closing price 04:00 PM EasternExtended Trading$80.98 +1.15 (+1.43%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Hims & Hers Health NYSE:HIMS$42.09 -22.13 (-34.46%) Closing price 03:59 PM EasternExtended Trading$43.78 +1.69 (+4.01%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
